Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3655071 | 1.00 | KMT2A (0.39) | KMT2AMEN1NPC1RAB9AHTR7 | |
| SCHEMBL959668 | 0.93 | NPC1 (0.43) | KMT2AMEN1NPC1RAB9AHTR7 | |
| SCHEMBL960035 | 0.88 | SMN1; SMN2 (0.45) | KMT2AMEN1NPC1RAB9AALOX5 | |
| SCHEMBL1463909 | 0.88 | NPC1 (0.37) | KMT2AMEN1NPC1RAB9AHTR7 | |
| SCHEMBL1463908 | 0.88 | NPC1 (0.37) | KMT2AMEN1NPC1RAB9AHTR7 | |
| SCHEMBL957442 | 0.82 | LMNA (0.38) | KMT2AMEN1NPC1ALOX5KDM4E | |
| SCHEMBL957441 | 0.82 | LMNA (0.38) | KMT2AMEN1NPC1ALOX5KDM4E | |
| SCHEMBL13077090 | 0.81 | SLC6A4 (0.42) | ALOX5ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15368826 | 0.80 | ALOX5 (0.42) | ALOX5ALDH1A1HPGDCYP1A2 | |
| SCHEMBL957646 | 0.80 | ALOX5 (0.42) | ALOX5ALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079861-B2 | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079861-B2 | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079861-B2 | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2220052-B1 | CYCLIC UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20100324045-A1 | CYCLIC UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100324045-A1 | CYCLIC UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100324045-A1 | CYCLIC UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| EP-2220052-A1 | CYCLIC UREA INHIBITORS OF 11 -HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009061498-A1 | CYCLIC UREA INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061498-A1 | CYCLIC UREA INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324045-A1 | CYCLIC UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD11B2 | KMT2A 4633/4885MEN1 944/4885NPC1 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.